Top Highlights for Aug 2015:
- Cipla bidding for Belgian drug maker Kremers Urban; Acquisition pegged at USD 1.3 billion.
- Cipla acquires two US-based generic Cos InvaGen Pharma and Exelan Pharma for $550 mn.
- Dr. Reddy's grab market rights for three Amgen drugs in India [Kyprolis® (carfilzomib),BLINCYTO® (blinatumomab) and Repatha™ (evolocumab)].
- Dr Reddy's scouting for acquisitions to expand their business in Europe. America is currently its biggest market (about 45 per cent of revenue).
- India based BPL Medical Technologies acquires UK based Penlon for expanding its presence in the critical care segment in 96 countries.
- Following signing of agreement in May 2015, Strides has now completed acquisition of Aspen in Australia.
- Sun Pharma completies acquisition of GSK's Opiates business in Australia.
- Dr. Reddy’s Laboratories starts new venture fund to invest in new technologies, startups..
For more such news and updates, please join our Group "Global Life Science Business in India" on LinkedIn.
Aagami Updates:
- Aagami CEO completes a successful business trip to India along with a New Zealand based Client; gets closer to deal making.
- Aagami gets repeat assignment from its Australian client for licensing of their technology and products in pipeline. Aagami has earlier brought about 3 partnerships in India for the same client.
- Aagami to participate in BIO EUROPE 2015 in Munich, Germany.
- Two Indian clients of Aagami move close to deal making ( one for US market, the other for Global).